News & Updates
Filter by Specialty:
Booster COVID-19 vacc cuts breakthrough infection risk, particularly in individuals with no immune dysfunction
Receipt of a booster dose of the COVID-19 vaccine reduces the risk of breakthrough COVID-19 infections* compared to full vaccination only, particularly among individuals without immunosuppressed/compromised conditions (ISC), according to a US study presented at CROI 2022.
Booster COVID-19 vacc cuts breakthrough infection risk, particularly in individuals with no immune dysfunction
17 Mar 2022
Investigational DP2 antagonist strikes out in eosinophilic asthma
The prostaglandin D2 receptor 2 (DP2) antagonist GB001 does not appear to significantly lower the risk of disease worsening in patients with moderate-to-severe eosinophilic asthma, according to data from a phase IIb trial.
Investigational DP2 antagonist strikes out in eosinophilic asthma
13 Mar 2022
Vitamin D deficiency tied to severe COVID-19
A systematic review and meta-analysis of >8,000 adult and elderly patients with COVID-19 showed a positive association between vitamin D deficiency (ie, 25(OH)D <50 nmol/L) and severe COVID-19.
Vitamin D deficiency tied to severe COVID-19
13 Mar 2022
Shorter antibiotic regimen enough in kids with pneumonia?
Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.
Shorter antibiotic regimen enough in kids with pneumonia?
10 Mar 2022
Delamanid-based regimens work against multidrug-resistant tuberculosis
The use of delamanid-containing regimens is safe and effective in the management of multidrug-resistant tuberculosis (MDR-TB), with high culture conversion and treatment success rates despite extensive resistance patterns, according to the results of a meta-analysis.
Delamanid-based regimens work against multidrug-resistant tuberculosis
10 Mar 2022
Female sex, hypertension, number of initial symptoms tied to long COVID risk
The risk of developing long COVID is high among women, hypertensives, and those with a higher number of initial symptoms, and these associations are independent of disease severity and clinical course, a study has found.